Nexviazyme®

Understanding Nexviazyme® 

Nexviazyme® (avalglucosidase alfa) is an enzyme replacement therapy (ERT) used to treat Pompe disease, a rare genetic disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). This deficiency leads to the buildup of glycogen in muscle cells, resulting in progressive muscle weakness and respiratory complications. By providing a functional form of GAA, Nexviazyme® helps break down excess glycogen, aiming to improve muscle function and respiratory capacity for individuals living with Pompe disease.

How Nexviazyme® Works:

• Replaces the missing GAA enzyme, aiding in glycogen breakdown.
• Reduces glycogen buildup in muscles, preventing further damage.
• Supports improved mobility and respiratory function in Pompe disease patients.

FDA Approval:

• Nexviazyme® (avalglucosidase alfa): Approved on August 6, 2021 for the treatment of Pompe disease.

For more information, please visit the Nexviazyme® patient website and speak with your healthcare provider to determine if Nexviazyme® is the right treatment option for you.